Evaluation of Post-Transplant Angiotensin II Type 1 Receptor Antibodies, Donor-Derived Cell-Free DNA, and Rejection in Heart Transplant Recipients
Fontan versus Non-Fontan Combined Heart-Liver Transplantation: Proceed but Cautiously
Heart-Kidney Transplantation Appears to Be Acceptable for Patients Greater Than 65 Years of Age
Impact of Cytomegalovirus Infection on mRNA Expression Utilizing the Molecular Microscope in Heart Transplant Recipients
Impact of Donor and Recipient Characteristics on Early Post-Transplant Donor-Derived Cell-Free DNA (dd-cfDNA) Scores
Increase in Exception and Extension Requests for Higher-Urgency Patients Under the New Heart Allocation Policy
Is Pathologic AMR Grading Scale Associated with the Presence of Donor-Specific Antibodies?
Longitudinal Characterization of Memory B Cells During Antibody Mediated Rejection Treated with Plasmapheresis, Bortezomib, and Belatacept in Heart Transplant Recipients
Outcome of Heart Transplantation After Pseudomonas Left Ventricular Assist Device Infection
Outcomes of a Standardized Antibody-Mediated Rejection (AMR) Treatment Protocol in Heart Transplant Recipients (HTR)
American Transplant Congress abstracts